Does CVS–Aetna Spell the End of Business as Usual?

The proposed $70 billion deal between CVS and Aetna would be a vertical merger that could heighten competition. By offering a new value proposition, the new company would aim to stay relevant despite encroachment by e-tailers and reduce total spending for care.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine Jg. 378; H. 7; S. 593 - 595
1. Verfasser: Dafny, Leemore S
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States Massachusetts Medical Society 15.02.2018
Schlagworte:
Acquisitions & mergers
Antitrust
Drug stores
Health care policy
Market shares
Pharmaceutical industry
Pharmacy
Prescription drugs
Primary care
ISSN:0028-4793, 1533-4406, 1533-4406
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The proposed $70 billion deal between CVS and Aetna would be a vertical merger that could heighten competition. By offering a new value proposition, the new company would aim to stay relevant despite encroachment by e-tailers and reduce total spending for care.
Bibliographie:SourceType-Scholarly Journals-1
content type line 14
ObjectType-Editorial-2
ObjectType-Commentary-1
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMp1717137